Shared Autoimmunity: A Case Series of 56 Patients with Immune Thrombocytopenia (ITP) Associated with Other Autoimmune Disorders

Lizbeth-Estefanía Díaz-Polo¹, Núria Pujol-Moix²,³*, Blanca Jiménez³, Carme Canals⁴, Edgardo Barranco-Charris¹, Eduardo Muñiz-Díaz⁴, Juan-Carlos Souto²

¹Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
²Hemostasis and Thrombosis Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
³Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
⁴Division of Immunohematology, Banc de Sang i Teixits de Catalunya, Barcelona, Spain

Email: npujolmoix@gmail.com

Received 8 June 2016; accepted 30 July 2016; published 3 August 2016

Copyright © 2016 by authors and OALib. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/

Abstract

The association of two or more autoimmune disorders in the same individual has been attributed to “shared autoimmunity” caused by the interaction between genetic and environmental factors. We present the retrospective analysis of 56 patients with Immune Thrombocytopenia (ITP) associated with other autoimmune disorders. Age, sex, clinical manifestations, platelet count, platelet autoantibodies and therapeutic responses were similar to those described in isolated ITP. However, we found a higher proportion of familial forms, suggesting a greater proportion of genetics in the etiopathogenesis of ITP associated with other autoimmune disorders. A total of 71 associated autoimmune disorders were found, the most frequent being systemic lupus erythematosus and Hashimoto thyroiditis. Most autoimmune disorders appeared before or after ITP but their simultaneous presentation was less frequent. Isolated laboratory markers of additional auto-immune disorders, mainly antinuclear and antithyroid antibodies, were found in about 20% of patients. Unlike ITP secondary to infectious or neoplastic diseases, ITP associated with other autoimmune disorders did not show significant differences with isolated ITP and it could appear indistinctly before, simultaneously, or after the associated disease. These characteristics suggest the need for a critical reconsideration of the term “secondary ITP” when ITP is associated with other autoimmune disorders.

Keywords

Shared Autoimmunity, Overlap Syndromes, Secondary Immune Thrombocytopenia,

*Corresponding author.

1. Introduction

The concurrence of 2 or more Autoimmune Disorders (AD) in the same individual has been described in patients with rheumatic connective tissue diseases, autoimmune-related thyroid diseases and inflammatory bowel diseases, among others [1]. These associations have been attributed to “shared autoimmunity” due to the interaction between genetic and environmental factors [2]. Immune Thrombocytopenia (ITP) has been found to be associated with diverse AD such as Graves disease, Hashimoto thyroiditis, Systemic Lupus Erythematosus (SLE), autoimmune hemolytic anemia, and antiphospholipid syndrome [3]-[5].

ITP is a hematologic disorder characterized by thrombocytopenia due to autoimmune destruction of sensitized platelets by antibodies that react with Glycoproteins (GP) expressed on platelets and megakaryocytes including GPIIb-IIIa, GPIb-IX and GPIa-IIa [6] [7]. Bleeding, mainly mucocutaneous, is the most common clinical manifestation of ITP [8]. According to the time of evolution, ITP is classified as recently diagnosed (less than 3 months), persistent (3 - 12 months) or chronic (more than 12 months) [8]. In adults, ITP presentation is usually insidious and sometimes the low platelet count might be an incidental finding [6]. ITP is also classified as primary, in the absence of other diseases, or secondary when it develops simultaneously or after other disorders that are usually autoimmune, infectious or neoplastic [8] [9]. The incidence of ITP is estimated about 2.9/100,000 person-year [10] and up to 5% - 10% of patients are classified as having secondary ITP [7]. However, the incidence of ITP associated with other AD, but not infectious or neoplastic disorders, is not known.

The objective of the present study was to describe a case series of patients with chronic ITP associated with other AD.

2. Methods

We retrospectively investigated the clinical records of adult patients (older than 16 years) with chronic ITP at Hospital de la Santa Creu i Sant Pau in Barcelona, Spain. Diagnosis was based on the currently accepted international diagnostic criteria for ITP [8]. From among these patients we selected a group of 56 that also had other AD. We collected patients’ demographic and general clinical data, including assessment of bleeding and signs and symptoms of the other AD. Laboratory analyses included platelet counts, general and organ-specific autoimmune markers, and platelet serological studies using the platelet immunofluorescence test [11]. We also investigated the date of onset of the AD with respect to that of ITP as well as the presence of other family members with ITP.

The study was conducted according to the Declaration of Helsinki and it was approved by the institutional ethics committee.

3. Results

The mean age of the patients at initial diagnosis was 49 years (range 16 - 90), and 64% were females (ratio female:male 1.78:1). The clinical manifestations of bleeding were generally mild, such as easy bruising and, in the majority of patients the thrombocytopenia was detected incidentally. Only 2 patients, both with very low platelet counts, had more remarkable symptoms of bleeding such as purpura and/or epistaxis. The mean platelet count at diagnosis was $67 \times 10^9/L$ (range 10 - 100). Serologic tests were only performed in 40 patients and 26 (65.0%) were positive. Of these, we found antibodies of the IgG class in 16 cases (61.6%), of the IgG + M class in 9 (34.6%), and of the IgG + M + A class in 1 (3.8%). Thirteen patients needed treatment due to platelet counts below $30 \times 10^9/L$ and/or to remarkable bleeding. Nine patients had a complete response with prednisone and/or splenectomy, 3 patients reached a hemostatic response with a variety of treatments, and 1 patient was refractory to all treatments assayed. Five patients (8.9%) had a first-degree relative with ITP, none of whom had an associated AD.

A total of 71 AD were found, the most frequent being SLE and Hashimoto thyroiditis (Table 1). Most pa-
patients had only 1 associated AD. However, 14 patients (25.0%) had 2 AD besides ITP, mainly Hashimoto thyroiditis combined with SLE or with Sjogren syndrome, and 1 patient (1.8%) had 3 associated disorders besides ITP: SLE, Hashimoto thyroiditis and thromboangiitis obliterans (Figure 1).

Most associated AD appeared after the ITP (34 disorders, 47.9%) or before the ITP (24 disorders, 33.8%). The least frequent situation was the simultaneous presentation of ITP and the associated AD (13 cases, 18.3%).

We found isolated laboratory markers of additional AD, without clinical manifestations, in 11 patients (19.6%) (Table 2). Most of these patients had SLE or Hashimoto thyroiditis associated with ITP and the only markers found were antinuclear antibodies, antithyroid peroxidase antibodies and lupus anticoagulant.

### Table 1. Autoimmune disorders associated with immune thrombocytopenia (ITP), and time of onset of them with respect to the onset of ITP.

<table>
<thead>
<tr>
<th>Autoimmune disorder</th>
<th>No. (%)</th>
<th>No. according to the time of onset with respect to the onset of ITP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Before</td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>20 (28.2)</td>
<td>9</td>
</tr>
<tr>
<td>Hashimoto thyroiditis</td>
<td>11 (15.5)</td>
<td>3</td>
</tr>
<tr>
<td>Sjogren syndrome</td>
<td>7 (9.8)</td>
<td>2</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>4 (5.6)</td>
<td>2</td>
</tr>
<tr>
<td>Autoimmune neutropenia</td>
<td>4 (5.6)</td>
<td>1</td>
</tr>
<tr>
<td>Atrophic gastritis</td>
<td>3 (4.2)</td>
<td>0</td>
</tr>
<tr>
<td>Autoimmune hemolytic anemia</td>
<td>3 (4.2)</td>
<td>0</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td>3 (4.2)</td>
<td>0</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>2 (2.9)</td>
<td>2</td>
</tr>
<tr>
<td>Graves disease</td>
<td>2 (2.9)</td>
<td>1</td>
</tr>
<tr>
<td>Thromboangiitis obliterans</td>
<td>2 (2.9)</td>
<td>0</td>
</tr>
<tr>
<td>Lichen planus</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td>Pyoderma gangrenosum</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td>Primary biliary cirrhosis</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td>Celiac disease</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td>Myasthenia gravis</td>
<td>1 (1.4)</td>
<td>1</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>1 (1.4)</td>
<td>1</td>
</tr>
<tr>
<td>Vitiligo</td>
<td>1 (1.4)</td>
<td>1</td>
</tr>
<tr>
<td>Antiphospholipid syndrome</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td>Autoimmune hepatitis</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td>Sarcoidosis</td>
<td>1 (1.4)</td>
<td>1</td>
</tr>
<tr>
<td>All</td>
<td>71 (100.0)</td>
<td>24</td>
</tr>
</tbody>
</table>

### Table 2. Patients with immune thrombocytopenia (ITP) and associated autoimmune disorders which also have isolated autoimmune markers (without clinical manifestations) of additional autoimmune disorders.

<table>
<thead>
<tr>
<th>Autoimmune disorders associated to ITP</th>
<th>No.</th>
<th>Isolated autoimmune markers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hashimoto thyroiditis</td>
<td>3</td>
<td>ANA</td>
</tr>
<tr>
<td>SLE</td>
<td>2</td>
<td>Anti-TPO</td>
</tr>
<tr>
<td>SLE + thromboangiitis obliterans</td>
<td>1</td>
<td>Anti-TPO</td>
</tr>
<tr>
<td>SLE + Hashimoto thyroiditis + thromboangiitis obliterans</td>
<td>1</td>
<td>Lupus anticoagulant</td>
</tr>
<tr>
<td>Autoimmune hepatitis</td>
<td>1</td>
<td>ANA</td>
</tr>
<tr>
<td>Atrophic gastritis</td>
<td>1</td>
<td>Anti-TPO</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td>1</td>
<td>ANA + anti-TPO</td>
</tr>
<tr>
<td>Ulcerative colitis + vitiligo</td>
<td>1</td>
<td>ANA + anti-TPO</td>
</tr>
</tbody>
</table>

SLE = systemic lupus erythematosus; ANA = antinuclear antibodies; anti-TPO = antithyroid peroxidase antibodies.
Figure 1. Graphical representation of patients with immune thrombocytopenia (ITP) and more than 1 associated autoimmune disorder. Boxes numbered “3” represent 3 patients with the same associations. All other boxes represent a single patient and his/her associated disorders. MS = multiple sclerosis, APS = antiphospholipid syndrome, SLE = systemic lupus erythematosus, TO = thromboangiitis obliterans, AIHA = autoimmune haemolytic anaemia.

4. Discussion

The concept of shared autoimmunity is used to refer to the development of 2 or more AD in the same patient or in a patient’s direct relatives [12]. These associations have also been referred to as “overlap syndrome” [1] [4] and “multiple autoimmune syndrome” [2]. Some types of “autoimmune polyglandular syndrome” are also expressions of shared autoimmunity [13]. The concept of “autoimmune clustering” has also been established to describe the tendency of certain AD to associate with each other. Two types of associations or clusters have been described: thyrogastric or organ-specific, and lupus-associated or multisystem. Some AD, however, can be found in both clusters and others do not associate [1].

The association between ITP and other AD—such as thyroid autoimmune diseases, SLE, inflammatory bowel diseases and autoimmune hemolytic anemia—has been recognized for a long time [3] [4] [9] [14]. However, to our knowledge, no previous studies have focused on ITP and its associated AD.

We studied a case series of 56 patients with chronic ITP and diverse associated AD as examples of shared autoimmunity. The ages of the patients ranged from young adults to the very elderly, and the sex ratio was higher for women, as generally described in ITP [14]. Clinical manifestations, platelet counts and therapeutic responses did not differ significantly from other case series of adult ITP [15]-[17]. Moreover, antiplatelet antibody studies, when performed, were positive in 65% of individuals with a predominance of IgG and IgG + M class of immunoglobulins. Other studies have also reported that the IgG class is that most commonly found in antiplatelet antibodies of ITP, either alone or associated with another immunoglobulin class [18] [19]. As in other reported case series [20], we found that some patients with ITP have first-degree relatives with the same disorder. Five of our patients had a relative with ITP, none of whom had an associated AD.

Of the 71 associated AD found in our patients that most frequently found was SLE, either as a single associated AD or in combination with another entity (Table 1, Figure 1). The prevalence of SLE in the general population is around 0.024% but in patients with ITP it has been reported as around 3.1% [14]. Moreover, it has been found that ITP develops in up to 1/3 of patients with SLE [9].

The second most frequently found associated AD was Hashimoto thyroiditis and, like SLE, it appeared either as a unique associated AD or together with another entity (Table 1, Figure 1). However, the thyroid AD Graves disease was much less frequent in our case series (Table 1). The association between thrombocytopenia and thyroid AD, including Hashimoto thyroiditis and Graves disease, has been previously described [4] [14], even in a familial context [3]. Nevertheless, specific publications about the association of ITP and Hashimoto thyroiditis...
associated with other AD either before, at the same time or after, be designated "associated ITP". Exposure, lymphoproliferative diseases or other causes retain the designation of "secondary ITP", and that ITP that frequently have isolated laboratory markers of different AD. For example, HIV infection can cause ITP but the inverse causal relationship does not exist. Other examples include ITP secondary to hepatitis C, to drug exposure or to lymphoproliferative diseases. In contrast, from the analysis of our patients and from previously published cases, it is clear that the associated AD can appear indistinctly before, after or simultaneously with ITP, suggesting a common cause leading to both processes rather than a causal link between them. Other authors have also discussed this issue, providing views similar to those presented here. Therefore, we suggest that ITP caused by virus infections, drug exposure, lymphoproliferative diseases or other causes retain the designation of "secondary ITP", and that ITP that occur associated with other AD either before, at the same time or after, be designated "associated ITP".

Eleven of our patients with ITP and 1 or more associated AD had laboratory markers of additional AD (Table 2). We found antinuclear antibodies, and/or antithyroid peroxidase antibodies in patients with diverse associated AD without being able to define any tendency towards a specific association between a laboratory marker and a clinical entity. Moreover, we found a lupus anticoagulant in the only patient with more than 2 associated AD.

Analysing the collection of associated AD found in our patients (Table 1, Figure 1), we tried to verify the situation of ITP within the established patterns of clustering in AD where it has been included in the lupus-associated cluster [1]. In our patients, the most frequently associated AD found was SLE. We also found other AD of the lupus-associated cluster such as Sjogren syndrome, autoimmune hemolytic anemia, rheumatoid arthritis and autoimmune hepatitis. However, our patients also had a remarkable number of thyroid AD, around 18.4%, including Hashimoto thyroiditis and Graves disease, which belong to the thyrogastric cluster. New studies in a high number of cases are needed to further clarify this issue.

The time of onset of the associated AD in our patients was variable. In most patients they occurred before or after ITP and, in a minority, they occurred simultaneously with ITP (Table 1). Looking at the time of onset of specific associated disorders (we analysed only those that appeared in more than 1 patient), we observed that most of them followed the general order of presentation, that is, preferably after or before ITP. Autoimmune neutropenia and autoimmune hemolytic anemia, nevertheless, tended to occur at the same time as ITP.

Other studies in patients with multiple AD have also found variations in the time of onset of the various disorders in the same patient. For example, the onset of thyroid AD has been previously described [4] [16] [21] simultaneously [21] [39] and after ITP [4] [21]. Another example is ulcerative colitis, which in most cases precedes ITP but has been seen to occur after ITP in others [29]. It is of interest to emphasize the predominance of the simultaneous occurrence of autoimmune hemolytic anemia or autoimmune neutropenia with ITP, with the 3 disorders together in 1 patient. It should be taken into account that the association of 2 or 3 autoimmune cytopenias, the so-called combined immunecytopenias [26] [40] or Evans syndrome [26] [41] has been recognized for a long time but the 3 have not always occurred simultaneously [5]. The variation in the time of onset of the associated AD with respect to ITP leads us to discuss the adequacy of the term “secondary ITP”, and the same could be said about other so-called “secondary autoimmune disorder” when they appear after another AD. In 2009, an international working group standardized the terminology, definitions and outcome criteria in ITP [8]. The term “secondary ITP” was proposed to broadly designate all forms of associated immunemediated thrombocytopenias, including those due to drug exposure or to an underlying disease such as SLE or HIV infection. However, not all illnesses which precede the presentation of secondary ITP are of the same nature. For example, HIV infection can cause ITP but the inverse causal relationship does not exist. Other examples include ITP secondary to hepatitis C, to drug exposure or to lymphoproliferative diseases. In contrast, from the analysis of our patients and from previously published cases, it is clear that the associated AD can appear indistinctly before, after or simultaneously with ITP, suggesting a common cause leading to both processes rather than a causal link between them. Other authors have also discussed this issue, providing views similar to those presented here. Therefore, we suggest that ITP caused by virus infections, drug exposure, lymphoproliferative diseases or other causes retain the designation of “secondary ITP”, and that ITP that occur associated with other AD either before, at the same time or after, be designated “associated ITP”.

Eleven of our patients with ITP and 1 or more associated AD had laboratory markers of additional AD (Table 2). We found antinuclear antibodies, and/or antithyroid peroxidase antibodies in patients with diverse associated AD without being able to define any tendency towards a specific association between a laboratory marker and a clinical entity. Moreover, we found a lupus anticoagulant in the only patient with more than 2 associated AD. Previous studies have shown that patients with ITP frequently have isolated laboratory markers of different AD. They generally appear in chronic forms of ITP, even in children [42] [43]. Antinuclear antibodies have been...
found in adult and pediatric patients with ITP, without this meaning a risk of developing SLE [43]-[45]. Besides, a number of patients with ITP show thyroid autoantibodies without any thyroid AD [4] [31] [45]. This has also been seen in childhood forms of ITP [46]. Furthermore, the presence of a lupus anticoagulant in patients recently diagnosed with ITP has been described as a risk factor for the development of antiphospholipid syndrome [47].

Autoimmunity is a complex phenomenon where the combination of genetic and environmental factors produces a breakdown of immune tolerance. Although the trigger process is poorly understood, autoantibodies against the body’s own tissues are generated, consequently producing injuries in various tissues and organs [34] [48] [49]. AD can occur in clusters or aggregations in individual patients and/or in different members of the same family. In 1997, Rose proposed that AD are unified by “shared or common threads” and he suggested adopting a unified approach to the overall AD [50]. Genetic studies carried out from this global perspective have established a genetic risk for autoimmunity based on HLA alleles and on variations in the genes that encode molecules affecting dendritic cells, B cells and T cells. Some of these genetic variations share different AD [1]. Apart from the genetic basis, AD can develop from other elements, such as female susceptibility, environmental factors and even random chance [1].

5. Conclusion

In conclusion, our case series of ITP associated with other AD showed no remarkable clinical or laboratory differences with the case series of isolated ITP other than a greater number of familial forms. According to shared autoimmunity theories, we can speculate that ITP patients with associated disorders and/or familial presentation have a greater proportion of genetics in their etiopathogenesis. Our patients had 1 or more associated AD and, some of them had isolated laboratory markers of additional disorders. Therefore, from a practical point of view, we recommend that the most frequent AD should be ruled out in all patients with ITP. This assessment should include first-degree relatives. This approach may help in the early diagnosis and treatment of the associated AD. As the onset of the associated AD differed with respect to ITP, we suggest that the expression “secondary ITP” should not be used for ITP that occurs after another AD. We propose reserving this expression for ITP caused by viral infections, drug exposure, lymphoproliferative diseases or other causes, and using the term “associated ITP” for ITP that precedes, coexists or follows other AD. We think that this nomenclature would be more consistent with the overall vision of autoimmunity.

Acknowledgements

This work was partially supported by: Instituto de Salud Carlos III of Spain (Grants PI14/00450 and RTICC RD12/0036/0071), Generalitat de Catalunya-AGAUR of Spain (Grant 2014-SGR-1281), Josep Carreras Leukaemia Research Institute and the Cellex Foundation.

References


